Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label studyPaola Tacchetti, Gianpietro Semenzato, Elena Zamagni et al.|The Lancet Haematology|2020Cited by 58
Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)Paola Tacchetti, Michèle Cavo, Carolina Terragna et al.|Blood|2011Cited by 1